Tiger Balm maker Haw Par should show its stripes, hunt for growth in alternative segments
The company’s smaller segments include investments and leisure-related services
Add BT as a preferred source
TIGER Balm ointment manufacturer Haw Par Corporation ’s business is roaring, with a resurgence of consumer sentiment for its healthcare products. Unlike its improving financials, however, its stock market performance has been skittish.
One problem for the mainboard-listed company is that it has no medicated oil peers on the local bourse.
While Haw Par is often grouped with healthcare counters, its focus on analgesic products for pain relief makes it inappropriate for investors to compare its metrics to “peers” in the sector, which include healthcare providers, healthcare equipment makers and pharmaceutical distributors.
TRENDING NOW
SIA sinks into the red with S$76 million Q1 loss as fuel costs jump
15-month wait-out curb lifted for private property owners buying HDB resale flats
ABSD deadline extended to up to 7 years for developers of large en bloc sites to encourage reuse of land
A ‘shadow bank’ hiding in Singapore’s Little India casts light on financial services gap
